Tuesday, February 14, 2012

Ranbaxy Rock Solid in Lipitor with 43% market Share

And also not to forget Lipitor will continue to be a low competition window post exclusivity expiry as patents are yet to be invalidated. Till now  Mylan/Matrix is the only other player to have received a tentative approval.
The 43% market share is of an expanded market (compared to pre-expiry), as therapeutic substitution is helping an expansion of the  atorvastatin market.

Ranbaxy also holds 43% share of the Caduet market.